IL151248A0 - Novel aryl fructose-1,6-bisphosphatase inhibitors - Google Patents

Novel aryl fructose-1,6-bisphosphatase inhibitors

Info

Publication number
IL151248A0
IL151248A0 IL15124801A IL15124801A IL151248A0 IL 151248 A0 IL151248 A0 IL 151248A0 IL 15124801 A IL15124801 A IL 15124801A IL 15124801 A IL15124801 A IL 15124801A IL 151248 A0 IL151248 A0 IL 151248A0
Authority
IL
Israel
Prior art keywords
fructose
novel aryl
bisphosphatase inhibitors
inhibitors
novel
Prior art date
Application number
IL15124801A
Other languages
English (en)
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of IL151248A0 publication Critical patent/IL151248A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826Acyclic unsaturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15124801A 2000-03-08 2001-03-07 Novel aryl fructose-1,6-bisphosphatase inhibitors IL151248A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18775000P 2000-03-08 2000-03-08
PCT/US2001/007452 WO2001066553A2 (en) 2000-03-08 2001-03-07 Novel aryl fructose-1,6-bisphosphatase inhibitors

Publications (1)

Publication Number Publication Date
IL151248A0 true IL151248A0 (en) 2003-04-10

Family

ID=22690309

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15124801A IL151248A0 (en) 2000-03-08 2001-03-07 Novel aryl fructose-1,6-bisphosphatase inhibitors
IL151248A IL151248A (en) 2000-03-08 2002-08-14 Inhibitors of aryl fructose – 1,6 – bisphosphatase

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151248A IL151248A (en) 2000-03-08 2002-08-14 Inhibitors of aryl fructose – 1,6 – bisphosphatase

Country Status (21)

Country Link
US (2) US6919322B2 (xx)
EP (2) EP1265907B9 (xx)
JP (1) JP2003525944A (xx)
KR (1) KR20020079988A (xx)
CN (2) CN1699383A (xx)
AT (1) ATE350385T1 (xx)
AU (2) AU4553201A (xx)
BR (1) BR0109062A (xx)
CA (1) CA2401706A1 (xx)
CZ (1) CZ20023018A3 (xx)
DE (1) DE60125734T2 (xx)
HK (1) HK1051865A1 (xx)
HU (1) HUP0300344A3 (xx)
IL (2) IL151248A0 (xx)
MX (1) MXPA02008722A (xx)
NO (1) NO20024240L (xx)
PL (1) PL357251A1 (xx)
RU (1) RU2002126616A (xx)
SK (1) SK12722002A3 (xx)
WO (1) WO2001066553A2 (xx)
ZA (1) ZA200207004B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DK1112275T3 (da) 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
IL149887A0 (en) * 1999-12-22 2002-11-10 Metabasis Therapeutics Inc Novel bisamidate phosphonate prodrugs
IL151248A0 (en) * 2000-03-08 2003-04-10 Metabasis Therapeutics Inc Novel aryl fructose-1,6-bisphosphatase inhibitors
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
TW200409643A (en) * 2002-07-23 2004-06-16 Sankyo Co Preventive agents for diabetes mellitus
FR2846327B1 (fr) * 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
BRPI0514372A (pt) * 2004-08-18 2008-06-10 Metabasis Therapeutics Inc inibidores de tiazol de frutose 1, 6-bisfosfatase
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
EP1825854A1 (en) * 2004-12-15 2007-08-29 Daiichi Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
CN106279283A (zh) * 2007-08-13 2017-01-04 症变治疗公司 新颖的葡糖激酶活化剂
EP2058308A1 (fr) 2007-11-12 2009-05-13 Merck Sante Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant.
EP3366686B9 (en) 2009-03-20 2021-08-04 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
US9006568B2 (en) 2012-02-15 2015-04-14 Phillips 66 Company Synthesis of photovoltaic conjugated polymers
CN104428294B (zh) 2012-04-20 2017-07-14 拜尔农科股份公司 N‑环烷基‑n‑[(杂环基苯基)亚甲基]‑(硫代)羧酰胺衍生物
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9691986B2 (en) 2012-12-03 2017-06-27 Solarmer Energy, Inc. Furan and selenophene derivatized benzo [1,2-b:4,5-b′] dithiophene-thienothiophene based conjugated polymers for high-efficiency organic solar cells
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
US9905769B2 (en) 2015-10-01 2018-02-27 Phillips 66 Company Process of manufacturing an electron transport material
US9911919B2 (en) 2015-10-01 2018-03-06 Phillips 66 Company Process of manufacturing an electron transport material
WO2017058406A1 (en) 2015-10-01 2017-04-06 Phillips 66 Company Formation of films for organic photovoltaics
US10312448B2 (en) 2015-10-01 2019-06-04 Phillips 66 Company Process of manufacturing an electron transport material
US10418555B2 (en) 2015-10-01 2019-09-17 Phillips 66 Company Formation of films for organic photovoltaics
US10604541B2 (en) 2016-07-22 2020-03-31 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN111116647B (zh) * 2019-12-02 2021-08-24 西安电子科技大学 一种具有hdac抑制活性的磷酸类化合物及其制备方法与用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL72851C (xx) * 1950-10-31 1900-01-01
US2683168A (en) * 1950-12-22 1954-07-06 California Research Corp Preparation of organo phosphonyl chlorides
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
GB2043073B (en) * 1979-02-13 1983-05-11 Symphar Sa Mono-and diphosphonate compounds
US4640701A (en) * 1984-04-17 1987-02-03 Ciba-Geigy Corporation Herbicidal phosphonic acid and phosphinic acid derivatives
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE3770982D1 (de) * 1986-04-24 1991-08-01 Fujisawa Pharmaceutical Co Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel.
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5045557A (en) * 1987-03-20 1991-09-03 Schering Agrochemicals Ltd. Imidazable fungicides and use thereof
US4968790A (en) 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
US4943629A (en) 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
DE69014562T2 (de) 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
JP3347723B2 (ja) 1990-06-13 2002-11-20 グラツィエル,アーノルド 含リンプロドラッグ
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5208235A (en) * 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole derivatives
US5278153A (en) * 1992-05-18 1994-01-11 E. R. Squibb & Sons, Inc. Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
AU683620B2 (en) 1992-09-28 1997-11-20 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
CA2126601A1 (en) 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
JP4086314B2 (ja) 1993-09-17 2008-05-14 ギリアード サイエンシーズ, インコーポレイテッド ヌクレオチドアナログ
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ES2210728T3 (es) * 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU767599B2 (en) 1998-03-06 2003-11-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
EP1070084A4 (en) 1998-03-16 2001-09-12 Ontogen Corp PIPERAZINE AS INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE)
DK1112275T3 (da) 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
DE19843383A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
NZ512219A (en) * 1998-12-24 2004-12-24 Metabasis Therapeutics Inc A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
MXPA01008937A (es) * 1999-03-05 2004-04-05 Metabasis Therapeutics Inc Nuevos profarmacos que contienen fosforo.
IL149887A0 (en) 1999-12-22 2002-11-10 Metabasis Therapeutics Inc Novel bisamidate phosphonate prodrugs
ATE346613T1 (de) 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
IL151248A0 (en) 2000-03-08 2003-04-10 Metabasis Therapeutics Inc Novel aryl fructose-1,6-bisphosphatase inhibitors
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CZ20035A3 (cs) 2000-07-06 2003-05-14 Metabasis Therapeutics, Inc. Kombinace FBPázových inhibitorů a antidiabetických činidel užitečná při léčení diabetes
BRPI0514372A (pt) 2004-08-18 2008-06-10 Metabasis Therapeutics Inc inibidores de tiazol de frutose 1, 6-bisfosfatase

Also Published As

Publication number Publication date
NO20024240L (no) 2002-11-08
HUP0300344A2 (hu) 2003-06-28
PL357251A1 (en) 2004-07-26
HUP0300344A3 (en) 2007-05-29
EP1607401A1 (en) 2005-12-21
NO20024240D0 (no) 2002-09-05
US6919322B2 (en) 2005-07-19
CZ20023018A3 (cs) 2003-01-15
ATE350385T1 (de) 2007-01-15
SK12722002A3 (sk) 2003-04-01
MXPA02008722A (es) 2004-05-05
IL151248A (en) 2007-06-17
US20050176684A1 (en) 2005-08-11
KR20020079988A (ko) 2002-10-21
DE60125734D1 (en) 2007-02-15
DE60125734T2 (de) 2007-10-25
US7371739B2 (en) 2008-05-13
HK1051865A1 (en) 2003-08-22
EP1265907A2 (en) 2002-12-18
AU4553201A (en) 2001-09-17
CN1516705A (zh) 2004-07-28
WO2001066553A2 (en) 2001-09-13
CA2401706A1 (en) 2001-09-13
JP2003525944A (ja) 2003-09-02
RU2002126616A (ru) 2004-03-20
BR0109062A (pt) 2002-11-26
AU2001245532B2 (en) 2005-08-11
WO2001066553A3 (en) 2002-03-14
ZA200207004B (en) 2003-12-01
EP1265907B9 (en) 2007-05-09
CN1699383A (zh) 2005-11-23
EP1265907B1 (en) 2007-01-03
US20020040014A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AU4553201A (en) Novel aryl fructose-1,6-bisphosphatase inhibitors
DK1112275T3 (da) Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
WO2001047935A3 (en) Novel bisamidate phosphonate prodrugs
RS93604A (xx) Supstituisani fenilacetamidi i njihova primena kao aktivatori glukokinaze
GB0213612D0 (en) Organic compounds
CA2499329A1 (en) Indole-3-carboxamides as glucokinase (gk) activators
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
FR13C0021I1 (xx)
AU2002351196A1 (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
RS20060320A (xx) Supstituisani indazol-o-glukozidi
MY142777A (en) Substituted indole-o-glucosides
UA86042C2 (xx) Заміщені індазол-о-глюкозиди$замещенные индазол-о-глюкозиды
DE69938192D1 (en) Imidazonaphthyridine
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
AU2002364302A8 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
DE60234424D1 (en) Biguanidderivate
WO2004053107A3 (en) Methods for treating diabetes
ZA981558B (en) Inclusion complexes in aqueous solution
WO2002055550A3 (en) Crystallization and structure determination of fema and/or fema-like proteins
GB0102408D0 (en) Chemical compounds
SE0102385D0 (sv) Screening methods
WO2003006688A3 (en) Methods for diagnosis and treatment of diseases associated with altered expression of gnas
SI1643999T1 (sl) Piridoksamin za uporabo v zdravljenju diabetične nefropatije pri diabetesu tipa II
RS20060323A (xx) Supstituisani indol-o-glukozidi

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed